Precigen (PGEN) Interest Expenses (2012 - 2026)
Precigen (PGEN) posted quarterly Interest Expenses of $2.9 million for Q1 2026, up 599.04% year-over-year from $416000.0 in Q1 2025, and up 11.55% quarter-over-quarter from $2.6 million in Q4 2025.
Analysis
Precigen (PGEN) Interest Expenses (2012 - 2026) Analysis & Trends
Precigen (PGEN) has reported Interest Expenses for 15 consecutive years, with $2.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Expenses rose 599.04% year-over-year to $2.9 million; the TTM figure through Mar 2026 stood at $8.6 million (up 135.56% YoY), while the FY2025 annual figure was $389.9 million, down 3.5% from the prior year.
- Interest Expenses climbed to $2.9 million in Q1 2026 per PGEN's latest filing, from $2.6 million in the prior quarter.
- Across five years, Interest Expenses topped out at $37.3 million in Q3 2025 and bottomed at -$1.4 million in Q4 2022.
- Historically, Interest Expenses has averaged $3.7 million across 5 years, with a median of $1.3 million in 2025.
- Annual changes were most pronounced in 2022 — Interest Expenses tumbled 112.14% — and 2025, when it soared 1866950.0%.
- Precigen's Interest Expenses stood at -$1.4 million in 2022, then surged by 100.5% to $7000.0 in 2023, then soared by 37828.57% to $2.7 million in 2024, then dropped by 1.81% to $2.6 million in 2025, then increased by 11.55% to $2.9 million in 2026.
- Business Quant data shows PGEN's Interest Expenses at $2.9 million in Q1 2026, $2.6 million in Q4 2025, and $37.3 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn | -1.00 Mn |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | 23.78 Mn |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn | 39.74 Mn |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | 93.62 Mn |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Precigen | 2.56 Bn | 2.56 Bn | 52.17 Mn | 2.95 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.95 Mn |
| Mar 31, 2026 | 2.91 Mn |
| Dec 31, 2025 | 2.96 Mn |
| Sep 30, 2025 | 902,000.00 |
| Mar 31, 2025 | 1,000.00 |
| Sep 30, 2024 | 2,000.00 |
| Jun 30, 2024 | 2,000.00 |
| Mar 31, 2024 | 2,000.00 |
| Dec 31, 2023 | 7,000.00 |
| Sep 30, 2023 | 1,000.00 |
| Jun 30, 2023 | 136,000.00 |
| Mar 31, 2023 | 324,000.00 |
| Dec 31, 2022 | 637,000.00 |
| Sep 30, 2022 | 2.04 Mn |
| Jun 30, 2022 | 2.06 Mn |
| Mar 31, 2022 | 2.04 Mn |
| Dec 31, 2021 | 4.85 Mn |
| Sep 30, 2021 | 4.77 Mn |
| Jun 30, 2021 | 4.63 Mn |
| Mar 31, 2021 | 4.54 Mn |